Вопросы современной педиатрии. 2013 12 (1) 6373)
 Скачать 253.33 Kb.
|
|
N. Engl. J. Med. 2007; 356: 659–661. 2. Frazer J. Infectious disease: Blowing in the wind. Nature. 2012; 484: 21–23. 3. Kushner H. I., Turner C. L., Bastian J. F., Burns, J. C. The narratives of Kawasaki disease. Bull. Hist. Med. 2004; 78: 410–439. 4. Kawasaki T., Kosaki F., Okawa S., Shigematsu I., Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974; 54: 271–276. 5. Kitamura S., Kawashima Y., Fujita T., Mori T., Oyama C. Aorto- coronary bypass grafting in a child with coronary artery obstruction due to mucocutaneous lymphnode syndrome: report of a case. Circulation. 1976; 53: 1035–1040. 6. Melish M. E., Hicks R., Lars R. Mucocutaneous lymph node syndrome in the U. S. Pediatr. Res. 1974; 8: 427. 7. Dorofeyeva G. D. Kawasaki disease (mucous-skin-lympho- glandular syndrome) in 6-year old boy. Pediatriya. Zhurnal imeni G. N. Speranskogo — Pediatrics. 1982; 4: pp. 65–66. 8. Zernov N. G., Kostikov M. V., Fedorov A. M. Kawasaki disease (mucous-skin-lympho-glandular syndrome) in children. Pediatriya. Zhurnal imeni G. N. Speranskogo — Pediatrics. 1983; 4: pp. 71–73. 9. Isayevam L. A., Lyskina G. A. Kawasaki disease (mucous-skin- lympho-glandular syndrome). Nodular periarthritis in children. Moscow: Medicine. 1984. Pp. 154–158. 10. Bregel L. V., Belozerov Yu. M., Subbotin V. M. Kawasaki disease in children — first clinical observations in Russia. Russian bulletin of perinatology and Pediatrics. 1998; 4: pp. 25–30. 11. Bregel L. V., Belozerov Yu. M., Subbotin V. M. Heart lesion in children with Kawasaki disease. Russian bulletin of perinatology and Pediatrics. 1998; 5: pp. 22–35. 12. Yanagawa H., Nakamura Y., Yashiro M., Ojima T, Tanihara S., Oki I., Zhang, T. Results of the nationwide epidemiologic survey of Kawasaki disease in 1995 and 1996 in Japan. Pediatrics. 1998; 102: 65. 13. Yanagawa H., Nakamura Y., Yashiro M., Uehara R., Oki I., Kayaba K. Incidence of Kawasaki disease in Japan: the nationwide surveys of 1999–2002. Pediatr. Int. 2006; 48: 356–361. 14. Nakamura Y., Yashiro M., Uehara R., Sadakane A., Chihara I., Aoyama Y., Kotani K., Yanagawa H. Epidemiologic features of Kawasaki disease in Japan: results of the 2007–2008 nationwide survey. J. Epidemio.l 2010; 20: 302–307. 15. Newburger J. W., Takahashi M., Gerber M. A., Gewitz M. H., Tani L. Y., Burns J. C., Shulman S. T., Bolger A. F., Ferrieri P., Baltimore R. S., Wilson W. R., Baddour L. M., Levison M. E., Pallasch T. J., Falace D. A., Taubert K. A. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004; 114: 1708–1733. 16. Holman R. C., Christensen K. Y., Belay E. D., Steiner C. A., Effler P. V., Miyamura J., Forbes S., Schonberger L. B., Melish M. Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Med. J. 2010; 69 (8): 194–197. 17. Burns J. C., Glode M. P. Kawasaki syndrome. Lancet. 2004; 364: 533–544. REFERENCES Непрерывное профессиональное образование. Rowley A. H., Baker S. C., Shulman S. T., Rand K. H., Tretiakova M. S., Perlman E. J., Garcia F. L., Tajuddin N. F., Fox L. M., Huang J. H., Ralphe J. C., Takahashi K., Flatow J., Lin S., Kalelkar M. B., Soriano B., Orenstein J. M. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a «new» virus associated with Kawasaki disease. J. Infect. Dis. 2011; 203: 1021–1030. 19. Abstracts of the 10th International Kawasaki Disease Symposium. February 7–10, 2012. Kyoto, Japan. Pediatr. Int. 2012; 54 (Suppl. 1): 38–142. 20. Rowley A. H., Shulman S. T. Pathogenesis and management of Kawasaki disease. Exp. Rev. Anti Infect. Ther. 2010; 8: 197–203. 21. Khor C. C., Davila S., Shimizu C., Sheng S., Matsubara T., Suzuki Y., Newburger J. W., Baker A., Burgner D., Breunis W., Kuijpers T., Wright V. J., Levin M., Hibberd M. L., Burns J. C. Genome- wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease. J. Med. Genet. 2011; 8: 467–472. 22. Mamtani M., Matsubara T., Shimizu C., Furukawa S., Akagi T., Onouchi Y., Hata A., Fujino A., He W., Ahuja S. K., Burns J. C. Association of CCR2–CCR5 haplotypes and CCL3L1 copy number with Kawasaki Disease, coronary artery lesions, and IVIG responses in Japanese children. PLoS One. 2010,5: e11458. 23. Abe J., Ebata R., Jibiki T., Yasukawa K., Saito H., Terai M. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J. All. Clin. Immunol. 2008; 122: 1008–1013. 24. Jennette J. C. Implications for pathogenesis of patterns of injury in small- and medium-sized-vessel vasculitis. Cleve Clin. J. Med. 2002; 69 (Suppl. 2): 33–38. 25. Senzaki H. Long-term outcome of Kawasaki disease. Circulation. 2008; 118: 2763–2772. 26. Suzuki A., Miyagawa-Tomita S., Nakazawa M., Yutani C. Remodeling of coronary artery lesions due to Kawasaki disease: comparison of arteriographic and immunohistochemical findings. Jpn Heart J. 2000; 41: 245–256. 27. Gordon J. B., Kahn A. M., Burns J. C. When children with kawasaki disease grow up myocardial and vascular complications in adulthood. J. Am. Coll. Cardiol. 2009; 4: 1911–1920. 28. Kato H., Sugimura T., Akagi T., Sato N., Hashino K., Maeno Y., Kazue T., Eto G., Yamakawa R. Long-term consequences of Kawasaki disease. A 10-to 21-year follow-up study of 594 patients. Circulation. 1996; 94: 1379–1385. 29. Burns J. Kawasaki disease outline for health care providers. e. p. URL: http://www-pediatrics.ucsd.edu/kawasaki. 2006. 30. Lyskina G. A., Shirinskaya O. G. Mucous-skin lymphonodular syndrome (Kawasaki syndrome). Diagnostics and treatment. Moscow: Vidar-M. 2008. 144 pp. 31. Baker A. L., Lu M., Minich L.L., Atz A. M., Klein G. L., Korsin R., Lambert L., Li J. S., Mason W., Radojewski E., Vetter V. L., Newburger J. W. Associated symptoms in the ten days before diagnosis of Kawasaki disease. J. Pediatr. 2009; 154: 592–595. 32. Printz B. F., Sleeper L. A., Newburger J. W., Minich L. L., Bradley T., Cohen M. S., Frank D., Li J. S., Margossian R., Shirali G., Takahashi M., Colan S. D. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J. Am. Coll. Cardiol. 2011; 57: 86–92. 33. Fujiwara H., Kawai C., Hamashima Y. Clinicopathologic study of the conduction systems in 10 patients with Kawasaki's disease (muco- cutaneous lymph node syndrome). Am. Heart J. 1978; 96: 744–750. 34. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease. Pediatr. Int. 2005; 47: 711–732. 35. Bregel L. V., Subbotin V. M. Clinical and echocardiographical signs of coronaritis in children with Kawasaki disease. Guideline for doctors. Irkutsk: RIO IGIUV. 2006. 101 pp. 36. Kim T., Choi W., Woo C. W., Choi B., Lee J., Lee K., Son C., Lee J. Predictive risk factors for coronary artery abnormalities in Kawasaki disease. Eur. J. Pediatr. 2007; 166: 421–425. 37. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr. Jpn. 1991; 33: 805–810. 38. McCrindle B. W., Li J. S., Minich L. L., Colan S. D., Atz A. M., Takahashi M., Vetter V. L., Gersony W. M., Mitchell P. D., Newbur- ger J. W. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation. 2007; 116: 174–179. 39. Iwai-Takano M., Oikawa M., Yamaki T., Yamaguchi O., Nakazato K., Ohsugi T., Kobayashi A., Watanabe M., Yaoita H., Maruyama Y. A case of recurrent myocardial infarction caused by a giant right coronary artery aneurysm. J. Am. Soc. Echocardiogr. 2007; 20: 1318; 1315–1318. 40. Kobayashi T., Sone K., Shinohara M., Kosuda T. Images in cardiovascular medicine. Giant coronary aneurysm of Kawasaki disease developing during postacute phase. Circulation. 1998; 98: 92–93. 41. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008)-digest version. Circ. J. 2010; 74: 1989–2020. 42. Brogan P. A., Bose A., Burgner D., Shingadia D., Tulloh R., Michie C., Klein N., Booy R., Levin M., Dillon M. J. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch. Dis. Child. 2002; 86: 286–290. 43. Lyskina G. A., Vinogradova O. I., Shirinskaya O. G., Bregel L. V., Subbotin V. M., Berns D. Clinic, diagnostics and treatment of Kawasaki syndrome. Clinical recommendations. Moscow. 2012. 62 pp. 44. Lyskina G. A., Shirinskaya O. G. Kawasaki syndrome in clinical practice. Clinic and treatment of debut of a disease. Moscow: Planida. 2012. 34 pp. 45. Sundel R. P. Update on the treatment of Kawasaki disease in childhood. Curr. Rheumatol. Rep. 2002; 4: 474–482. 46. Oates-Whitehead R. M., Baumer J. H., Haines L., Love S., Maconochie I. K., Gupta A., Roman K., Dua J. S., Flynn I. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst. Rev. 2003: CD004000. 47. Sakata K., Hamaoka K., Ozawa S., Niboshi A., Yoshihara T., Nishiki T., Nakagawa Y., Kazuta K., Morimoto Y., Kamiya Y., Yamamoto T., Horii Y., Kido S. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. Eur. J. Pediatr. 2007; 166: 565–571. 48. Baer A. Z., Rubin L. G., Shapiro C. A., Sood S. K., Rajan S., Shapir Y., Romano A., Bierman F. Z. Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome. Arch. Pediatr. Adolesc. Med. 2006; 160: 686–690. 49. Williams R. V., Minich L. L., Tani L. Y. Pharmacological therapy for patients with Kawasaki disease. Paediatr. Drugs. 2001; 3: 649–660. 50. Burns J. C., Mason W. H., Hauger S. B. Infliximab treatment for refractory Kawasaki syndrome. J. Pediatr. 2005; 146: 662–667. 51. Yellen E. S., Gauvreau K., Takahashi M., Burns J. C., Shulman S., Baker A. L., Innocentini N., Zambetti C., Pan- cheri J. M., Ostrow A., Frazer J. R., Sundel R. P., Fulton D. R., Newburger J. W. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics. 125: 234–241. 52. Millar K., Manlhiot C., Yeung R. S., Somji Z., McCrindle B. W. Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression. Int. J. Cardiol. 2010. doi: 10.1016/j. ijcard.2010.08.070 53. Burns J. C., Best B. M., Mejias A., Mahony L., Fixler D. E., Jafri H. S., Melish M. E., Jackson M. A., Asmar B. I., Lang D. J., Connor J. D., Capparelli E. V., Keen M. L., Mamun K., Keenan G. F., Ramilo O. Infliximab treatment of intravenous immunoglobulin- resistant Kawasaki disease. J. Pediatr. 2008; 153: 833–838. ВОПРОСЫ СОВРЕМЕННОЙ ПЕДИАТРИИ /2013/ ТОМ 12/ № 1 54. Raman V., Kim J., Sharkey A., Chatila T. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr. Infect. Dis. J. 2001; 20: 635–637. 55. Furukawa T., Kishiro M., Akimoto K., Nagata S., Shimizu T., Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin- resistant Kawasaki disease. Arch. Dis. Child. 2008; 93: 142–146. 56. Newburger J. W., Sleeper L. A., McCrindle B. W., Minich L. L., Gersony W., Vetter V. L., Atz A. M., Li J. S., Takahashi M., Baker A. L., Colan S. D., Mitchell P. D., Klein G. L., Sundel R. P. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N. Engl. J. Med. 2007; 356: 663–675. 57. Sleeper L. A., Minich L. L., McCrindle B. M., Li J. S., Mason W., Colan S. D., Atz A. M., Printz B. F., Baker A., Vetter V. L., Newburger J. W. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J. Pediatr. 2011; 158: 831–835. 58. Kobayashi T., Saji T., Otani T., Takeuchi K., Nakamura T., Arakawa H., Kato T., Hara T., Hamaoka K., Ogawa S., Miura M., Nomura Y., Fuse S., Ichida F., Seki M., Fukazawa R., Ogawa C., Furuno K., Tokunaga H., Takatsuki S., Hara S., Morikawa A. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012; 379: 1613–1620. |